# US 2016/0355599 A1 · Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355599 A1
- Document ID: US20160355599A1
- Status: Published application
- Kind: A1
- Application number: 15/146,294
- Filed: 2016-05-04
- Published: 2016-12-08
- Earliest claimed: 2015-05-04
- Assignees: CytomX Therapeutics, Inc.
- Applicants: CytomX Therapeutics, Inc.
- Inventors: Jason Gary Sagert; Kimberly Ann Tipton; Jonathan Alexander Terrett; Shweta Singh; Annie Yang Weaver; Luc Roland Desnoyers
- Web page: https://patentgrep.com/patent/US20160355599A1

## CPC

- C07K 16/2881: {against CD71}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0058: {Antibodies}
- A61P 35/00: Antineoplastic agents
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K 2319/50: containing protease site
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

## Claims

### Claim 1

An isolated antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian CD71, wherein the AB specifically binds human CD71 and cynomolgus monkey CD71.

### Claim 2 (depends on 1)

The AB of claim 1, wherein the AB comprises the VH CDR1 sequence GYTFTSYWMH (SEQ ID NO: 9); the VH CDR2 sequence AIYPGNSETG (SEQ ID NO: 10); the VH CDR3 sequence ENWDPGFAF (SEQ ID NO: 11); the VL CDR1 sequence SASSSVYYMY (SEQ ID NO: 12) or CRASSSVYYMY (SEQ ID NO: 13); the VL CDR2 sequence STSNLAS (SEQ ID NO: 14); and the VL CDR3 sequence QQRRNYPYT (SEQ ID NO: 15).

### Claim 3 (depends on 1)

The AB of claim 1, wherein the AB comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-8.

### Claim 4 (depends on 2)

An isolated antibody or antigen binding fragment thereof that binds to the same epitope on human CD71 and/or cynomolgus monkey CD71 as the AB of claim 2.

### Claim 5 (depends on 2)

An isolated antibody or antigen binding fragment thereof that cross-competes with the AB of claim 2 for binding to human CD71 and/or cynomolgus monkey CD71.

### Claim 6

An activatable antibody that, in an activated state, specifically binds to mammalian CD71 comprising:
an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian CD71, wherein the AB specifically binds human CD71 and cynomolgus monkey CD71;
a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to CD71 when the activatable antibody is in an uncleaved state; and
a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease.

### Claim 7 (depends on 6)

The activatable antibody of claim 6, wherein the MM has one or more of the characteristics selected from the group consisting of:
(i) the MM has a dissociation constant for binding to the AB that is greater than the dissociation constant of the AB to CD71;
(ii) the MM does not interfere or compete with the AB for binding to CD71 when the activatable antibody is in a cleaved state;
(iii) the MM is a polypeptide of no more than 40 amino acids in length;
(iv) the MM polypeptide sequence is different from that of human CD71;
(v) the MM polypeptide sequence is no more than 50% identical to any natural binding partner of the AB; and
(vi) the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-295 and 297-314.

### Claim at position 8

-13. (canceled)

### Claim 14 (depends on 6)

The activatable antibody of claim 6, wherein the CM has one or more of the characteristics selected from the group consisting of:
(i) the CM is a substrate for a protease that is active in diseased tissue; and
(ii) the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 356-423, 680-698, 713, 714, and 789-808.

### Claim at position 10

-16. (canceled)

### Claim 17 (depends on 6)

The activatable antibody of claim 6, wherein the antigen binding fragment thereof is selected from the group consisting of a Fab fragment, a F(ab′)2 fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody.

### Claim 18

(canceled)

### Claim 19 (depends on 6)

The activatable antibody of claim 6, wherein AB has one or more of the characteristics selected from the group consisting of:
(i) the AB comprises the VH CDR1 sequence GYTFTSYWMH (SEQ ID NO: 9); the VH CDR2 sequence AIYPGNSETG (SEQ ID NO: 10); the VH CDR3 sequence ENWDPGFAF (SEQ ID NO: 11); the VL CDR1 sequence SASSSVYYMY (SEQ ID NO: 12) or CRASSSVYYMY (SEQ ID NO: 13); the VL CDR2 sequence STSNLAS (SEQ ID NO: 14); and the VL CDR3 sequence QQRRNYPYT (SEQ ID NO: 15); and
(ii) the AB comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-8.

### Claim 20

(canceled)

### Claim 21 (depends on 6)

The activatable antibody of claim 6, wherein the AB is linked to the CM.

### Claim 22 (depends on 6)

The activatable antibody of claim 6, wherein the AB is linked directly to the CM.

### Claim 23 (depends on 6)

The activatable antibody of claim 6, wherein the AB is linked to the CM via a linking peptide.

### Claim 24 (depends on 6)

The activatable antibody of claim 6, wherein the MM is linked to the CM such that the activatable antibody in an uncleaved state comprises the structural arrangement from N-terminus to C-terminus as follows: MM-CM-AB or AB-CM-MM.

### Claim 25 (depends on 6)

The activatable antibody of claim 6, wherein the activatable antibody comprises a linking peptide between the MM and the CM, a linking peptide between the CM and the AB, or both a linking peptide between the MM and the CM and a linking peptide between the CM and the AB.

### Claim 26

(canceled)

### Claim 27 (depends on 6)

The activatable antibody of claim 6, wherein the activatable antibody comprises a first linking peptide (LP1) and a second linking peptide (LP2), and wherein the activatable antibody in the uncleaved state has the structural arrangement from N-terminus to C-terminus as follows: MM-LP1-CM-LP2-AB or AB-LP2-CM-LP1-MM.

### Claim 28 (depends on 27)

The activatable antibody of claim 27, wherein the two linking peptides are not identical to each other.

### Claim 29 (depends on 27)

The activatable antibody of claim 27, wherein each of LP1 and LP2 is a peptide of about 1 to 20 amino acids in length.

### Claim 30 (depends on 6)

The activatable antibody of claim 6, wherein the activatable antibody has one or more of the characteristics selected from the group consisting of:
(a) the activatable antibody comprises the heavy chain sequence of SEQ ID NO: 325 or 699 and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 327, 329, 331, 333, 335, 337, 650, 652, 654, 656, 658, 660, 670-673, 701-712, and 721-788;
(b) the activatable antibody comprises a combination of amino acid sequences, wherein the combination of amino acid sequences is selected from a single row in Table D, wherein for a given combination,
(i) the heavy chain of the AB comprises the amino acid sequences of the VH CDR sequences corresponding to the given combination in the single row listed in Table D,
(ii) the light chain of the AB comprises the amino acid sequences of the VL CDR sequences corresponding to the given combination in the single row listed in Table D,
(iii) the MM comprises the amino acid sequence of the mask sequence (MM) corresponding to the given combination in the single row listed in Table D, and
(iv) the CM comprises the amino acid sequence of the substrate sequence (CM) corresponding to the given combination in the single row listed in Table D;
(c) the activatable antibody comprises a combination of amino acid sequences, wherein for a given combination of amino acid sequences,
(i) the heavy chain of the AB comprises the amino acid sequences of the VH sequence or VH CDR sequences selected from the group consisting of: the VH sequence or VH CDR sequences listed in the corresponding column of Table E,
(ii) the light chain of the AB comprises the amino acid sequences of the VL sequence or VL CDR sequences selected from the group consisting of: the VL sequence or VL CDR sequences listed in the corresponding column of Table E,
(iii) the MM comprises the amino acid sequence of the mask sequence (MM) selected from the group consisting of: the MM sequences listed in the corresponding column of Table E, and
(iv) the CM comprises the amino acid sequence of the substrate sequence (CM) selected from the group consisting of: the CM sequences listed in the corresponding column of Table E; and
(d) the activatable antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-8, 809-836, and 841-908.

### Claim at position 25

-32. (canceled)

### Claim 33

An activatable antibody comprising an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian CD71, a MM, and a CM, wherein the activatable antibody has one or more of the following characteristics selected from the group consisting of:
(i) the activatable antibody comprises a heavy chain sequence of SEQ ID NOS: 325 or 699; and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 327, 329, 331, 333, 335, 337, 650, 652, 654, 656, 658, 660, 670-673, 701-712, and 721-788;
(ii) the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-295 and 297-314, and the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 356-423, 680-698, 713, 714, and 789-808;
(iii) the AB comprises the VH CDR1 sequence GYTFTSYWMH (SEQ ID NO: 9), the VH CDR2 sequence AIYPGNSETG (SEQ ID NO: 10), the VH CDR3 sequence ENWDPGFAF (SEQ ID NO: 11), the VL CDR1 sequence SASSSVYYMY (SEQ ID NO: 12) or CRASSSVYYMY (SEQ ID NO: 13), the VL CDR2 sequence STSNLAS (SEQ ID NO: 14), and the VL CDR3 sequence QQRRNYPYT (SEQ ID NO: 15);
(iv) the activatable antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-8, 809-836, and 841-908; and
(v) the AB comprises the VH CDR1 sequence GYTFTSYWMH (SEQ ID NO: 9), the VH CDR2 sequence AIYPGNSETG (SEQ ID NO: 10), the VH CDR3 sequence ENWDPGFAF (SEQ ID NO: 11), the VL CDR1 sequence SASSSVYYMY (SEQ ID NO: 12) or CRASSSVYYMY (SEQ ID NO: 13), the VL CDR2 sequence STSNLAS (SEQ ID NO: 14), and the VL CDR3 sequence QQRRNYPYT (SEQ ID NO: 15), the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-295 and 297-314, and the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 356-423, 680-698, 713, 714, and 789-808.

### Claim at position 27

-37. (canceled)

### Claim 38 (depends on 2)

An activatable anti-CD71 antibody comprising
an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian CD71, wherein the AB specifically binds to the same epitope on human CD71 and/or cynomolgus monkey CD71 as the isolated antibody of claim 2 or wherein the AB specifically cross-competes with the isolated antibody of claim 2 for binding to human CD71 and/or cynomolgus monkey CD71;
a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to CD71 when the activatable antibody is in an uncleaved state; and
a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease.

### Claim 39

(canceled)

### Claim 40 (depends on 6)

A conjugated activatable antibody comprising the activatable antibody of claim 6 conjugated to an agent.

### Claim 41 (depends on 40)

The conjugated activatable antibody of claim 40, wherein the agent has one or more of the characteristics selected from the group consisting of:
(a) the agent is a toxin or fragment thereof;
(b) the agent is a microtubule inhibitor;
(c) the agent is a nucleic acid damaging agent;
(d) the agent is a dolastatin or a derivative thereof;
(e) the agent is an auristatin or a derivative thereof;
(f) the agent is a maytansinoid or a derivative thereof;
(g) the agent is a duocarmycin or a derivative thereof;
(h) the agent is a calicheamicin or a derivative thereof;
(i) the agent is a pyrrolobenzodiazepine or a derivative thereof;
(j) the agent is auristatin E or a derivative thereof;
(k) the agent is monomethyl auristatin E (MMAE);
(l) the agent is monomethyl auristatin D (MMAD);
(m) the agent is the maytansinoid DM1;
(n) the agent is the maytansinoid DM4;
(o) the agent is a detectable moiety; and
(p) the agent is a diagnostic agent.

### Claim at position 32

-50. (canceled)

### Claim 51 (depends on 40)

The conjugated activatable antibody of claim 40, wherein the agent is conjugated to the AB via a linker.

### Claim 52 (depends on 51)

The conjugated activatable antibody of claim 51, wherein the linker with which the agent is conjugated to the AB comprises an SPDB moiety, a vc moiety, or a PEG2-vc moiety.

### Claim 53 (depends on 40)

The conjugated activatable antibody of claim 40, wherein the agent is a toxin conjugated to the AB via a linker, and wherein the linker and the toxin conjugated to the AB comprise a moiety selected from the group consisting of: an SPDB-DM4 moiety, a vc-MMAD moiety, a vc-MMAE moiety, a vc-duocarmycin moiety, or a PEG2-vc-MMAD moiety.

### Claim 54 (depends on 51)

The conjugated activatable antibody of claim 51, wherein the linker is a cleavable linker.

### Claim 55 (depends on 51)

The conjugated activatable antibody of claim 51, wherein the linker is a non-cleavable linker.

### Claim at position 38

-57. (canceled)

### Claim 58

A conjugated activatable antibody that, in an activated state, binds CD71 comprising:
(a) an activatable antibody comprising:
(i) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian CD71, wherein the AB specifically binds human CD71 and cynomolgus monkey CD71;
(ii) a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to CD71 when the activatable antibody is in an uncleaved state; and
(iii) a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease; and
(b) an agent conjugated to the AB.

### Claim 59 (depends on 58)

The conjugated activatable antibody of claim 58, wherein the agent is selected from the group consisting of a dolastatin or a derivative thereof, an auristatin or a derivative thereof, a maytansinoid or a derivative thereof, a duocarmycin or a derivative thereof, a calicheamicin or a derivative thereof, a pyrrolobenzodiazepine or a derivative thereof, auristatin E, monomethyl auristatin F (MMAF), monomethyl auristatin E (MMAE), monomethyl auristatin D (MMAD), maytansinoid DM4, maytansinoid DM1, a duocarmycin, a calicheamicin, a pyrrolobenzodiazepine, and a pyrrolobenzodiazepine dimer.

### Claim 60

(canceled)

### Claim 61 (depends on 58)

The conjugated activatable antibody of claim 58, wherein the agent is conjugated to the AB via a linker.

### Claim 62 (depends on 61)

The conjugated activatable antibody of claim 61, wherein the linker with which the agent is conjugated to the AB comprises an SPDB moiety, a vc moiety, or a PEG2-vc moiety.

### Claim 63 (depends on 58)

The conjugated activatable antibody of claim 58, wherein the agent is a toxin conjugated to the AB via a linker, and wherein the linker and the toxin conjugated to the AB comprise a moiety selected from the group consisting of: an SPDB-DM4 moiety, a vc-MMAD moiety, a vc-MMAE moiety, a vc-duocarmycin moiety, or a PEG2-vc-MMAD moiety.

### Claim 64 (depends on 58)

The conjugated activatable antibody of claim 58, wherein the activatable antibody has one or more of the characteristics selected from the group consisting of:
(i) the activatable antibody comprises the VH CDR1 sequence GYTFTSYWMH (SEQ ID NO: 9); the VH CDR2 sequence AIYPGNSETG (SEQ ID NO: 10); the VH CDR3 sequence ENWDPGFAF (SEQ ID NO: 11); the VL CDR1 sequence SASSSVYYMY (SEQ ID NO: 12) or CRASSSVYYMY (SEQ ID NO: 13); the VL CDR2 sequence STSNLAS (SEQ ID NO: 14); and the VL CDR3 sequence QQRRNYPYT (SEQ ID NO: 15);
(ii) the activatable antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-8, 809-836, and 841-908; and
(iii) the activatable antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NOS: 325 or 699, and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 327, 329, 331, 333, 335, 337, 650, 652, 654, 656, 658, 660, 670-673, 701-712, and 721-788.

### Claim 65

(canceled)

### Claim 66 (depends on 58)

The conjugated activatable antibody of claim 58, wherein the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-295 and 297-314.

### Claim 67

(canceled)

### Claim 68 (depends on 58)

The conjugated activatable antibody of claim 58, wherein the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 356-423, 680-698, 713, 714, and 789-808.

### Claim 69

(canceled)

### Claim 70 (depends on 58)

The conjugated activatable antibody of claim 58, wherein the activatable antibody has one or more of the following characteristics selected from the group consisting of:
(i) the activatable antibody comprises a combination of amino acid sequences, wherein the combination of amino acid sequences is selected from a single row in Table D, wherein for a given combination,
(a) the heavy chain of the AB comprises the amino acid sequences of the VH CDR sequences corresponding to the given combination in the single row listed in Table D,
(b) the light chain of the AB comprises the amino acid sequences of the VL CDR sequences corresponding to the given combination in the single row listed in Table D,
(c) the MM comprises the amino acid sequence of the mask sequence (MM) corresponding to the given combination in the single row listed in Table D, and
(d) the CM comprises the amino acid sequence of the substrate sequence (CM) corresponding to the given combination in the single row listed in Table D; and
(ii) the activatable antibody comprises a combination of amino acid sequences, wherein for a given combination of amino acid sequences,
(a) the heavy chain of the AB comprises the amino acid sequences of the VH sequence or VH CDR sequences selected from the group consisting of: the VH sequence or VH CDR sequences listed in the corresponding column of Table E,
(b) the light chain of the AB comprises the amino acid sequences of the VL sequence or VL CDR sequences selected from the group consisting of: the VL sequence or VL CDR sequences listed in the corresponding column of Table E,
(c) the MM comprises the amino acid sequence of the mask sequence (MM) selected from the group consisting of: the MM sequences listed in the corresponding column of Table E, and
(d) the CM comprises the amino acid sequence of the substrate sequence (CM) selected from the group consisting of: the CM sequences listed in the corresponding column of Table E.

### Claim at position 52

-72. (canceled)

### Claim 73

A conjugated antibody comprising:
(a) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian CD71, wherein the AB comprises:
(i) the VH CDR1 sequence GYTFTSYWMH (SEQ ID NO: 9); the VH CDR2 sequence AIYPGNSETG (SEQ ID NO: 10); the VH CDR3 sequence ENWDPGFAF (SEQ ID NO: 11); the VL CDR1 sequence SASSSVYYMY (SEQ ID NO: 12) or CRASSSVYYMY (SEQ ID NO: 13); the VL CDR2 sequence STSNLAS (SEQ ID NO: 14); and the VL CDR3 sequence QQRRNYPYT (SEQ ID NO: 15), or
(ii) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-8; and
(b) an agent conjugated to the AB, wherein the agent is selected from the group consisting of auristatin E, monomethyl auristatin F (MMAF), monomethyl auristatin E (MMAE), monomethyl auristatin D (MMAD), maytansinoid DM4, maytansinoid DM1, a calicheamicin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, and a duocarmycin.

### Claim 74

A conjugated activatable antibody that, in an activated state, specifically binds to mammalian CD71, comprising:
(a) an activatable antibody comprising:
(i) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian CD71, wherein the AB specifically binds human CD71 and cynomolgus monkey CD71;
(ii) a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to CD71 when the activatable antibody is in an uncleaved state;
(iii) a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease; and
(b) an agent conjugated to the AB,
wherein the activatable antibody comprises:
(i) the VH CDR1 sequence GYTFTSYWMH (SEQ ID NO: 9); the VH CDR2 sequence AIYPGNSETG (SEQ ID NO: 10); the VH CDR3 sequence ENWDPGFAF (SEQ ID NO: 11); the VL CDR1 sequence SASSSVYYMY (SEQ ID NO: 12) or CRASSSVYYMY (SEQ ID NO: 13); the VL CDR2 sequence STSNLAS (SEQ ID NO: 14); and the VL CDR3 sequence QQRRNYPYT (SEQ ID NO: 15), or
(ii) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-8, 809-836, and 841-908, or
(iii) a heavy chain comprising the amino acid sequence of SEQ ID NOS: 325 or 699, and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 327, 329, 331, 333, 335, 337, 650, 652, 654, 656, 658, 660, 670-673, 701-712, and 721-788; and
wherein the agent is selected from the group consisting of auristatin E, monomethyl auristatin F (MMAF), monomethyl auristatin E (MMAE), monomethyl auristatin D (MMAD), maytansinoid DM4, maytansinoid DM1, a calicheamicin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, and a duocarmycin.

### Claim 75 (depends on 74)

The conjugated activatable antibody of claim 74, wherein the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-295 and 297-314.

### Claim 76

(canceled)

### Claim 77 (depends on 74)

The conjugated activatable antibody of claim 74, wherein the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 356-423, 680-698, 713, 714, and 789-808.

### Claim 78

(canceled)

### Claim 79 (depends on 74)

The conjugated activatable antibody of claim 74, wherein the agent is conjugated to the AB via a linker, and wherein the linker to which the agent is conjugated to the AB comprises an SPDB moiety, a vc moiety, or a PEG2-vc moiety.

### Claim 80 (depends on 74)

The conjugated activatable antibody of claim 74, wherein the agent is a toxin conjugated to the AB via a linker, and wherein the linker and the toxin conjugated to the AB comprise a moiety selected from the group consisting of: an SPDB-DM4 moiety, a vc-MMAD moiety, a vc-MMAE moiety, a vc-duocarmycin moiety, or a PEG2-vc-MMAD moiety.

### Claim 81

A conjugated activatable antibody or conjugated antibody comprising:
an antibody or antigen binding fragment thereof (AB) that, in an activated state, binds CD71; and
a toxin conjugated to the AB via a linker,
wherein the conjugated activatable antibody or the conjugated antibody comprises amino acid sequences, a linker, and a toxin selected from a single row in Table F, wherein for the given combination:
(a) the AB comprises a heavy chain comprising the amino acid sequence of the heavy chain sequence or heavy chain variable domain sequence corresponding to the given combination in the single row listed in Table F,
(b) the AB comprises a light chain comprising the amino acid sequence of the light chain sequence or light chain variable domain sequence corresponding to the given combination in the single row listed in Table F, and
(c) the linker and the toxin comprise the linker and the toxin corresponding to the given combination in the single row listed in Table F.

### Claim 82 (depends on 6)

A pharmaceutical composition comprising the activatable antibody of claim 6; and a carrier.

### Claim 83 (depends on 82)

The pharmaceutical composition of claim 82 comprising an additional agent.

### Claim 84 (depends on 83)

The pharmaceutical composition of claim 83, wherein the additional agent is a therapeutic agent.

### Claim 85 (depends on 6)

An isolated nucleic acid molecule encoding the activatable antibody of claim 6.

### Claim 86 (depends on 85)

A vector comprising the isolated nucleic acid molecule of claim 85.

### Claim 87 (depends on 85)

A method of producing an activatable antibody by culturing a cell under conditions that lead to expression of the activatable antibody, wherein the cell comprises the nucleic acid molecule of claim 85.

### Claim 88 (depends on 6)

A method of manufacturing an activatable antibody that, in an activated state, binds CD71, the method comprising:
(a) culturing a cell comprising a nucleic acid construct that encodes the activatable antibody under conditions that lead to expression of the activatable antibody, wherein the activatable antibody comprises an activatable antibody of claim 6;
and
(b) recovering the activatable antibody.

### Claim 89 (depends on 40)

A method of treating, alleviating a symptom of, or delaying the progression of a disorder or disease in which diseased cells express CD71 comprising administering a therapeutically effective amount of the conjugated activatable antibody of claim 40 to a subject in need thereof.

### Claim 90 (depends on 89)

The method of claim 89, wherein the disorder or disease is cancer.

### Claim 91 (depends on 40)

A method of treating, alleviating a symptom of, or delaying the progression of a disorder or disease associated with cells expressing CD71 comprising administering a therapeutically effective amount of the conjugated activatable antibody of claim 40 to a subject in need thereof.

### Claim 92 (depends on 91)

The method of claim 91, wherein the disorder or disease associated with cells expressing CD71 is cancer.

### Claim 93 (depends on 92)

The method of claim 92, wherein the cancer is an adenocarcinoma, a bile duct (biliary) cancer, a bladder cancer, a bone cancer, a breast cancer, a triple-negative breast cancer, a Her2-negative breast cancer, a carcinoid cancer, a cervical cancer, a cholangiocarcinoma, a colorectal cancer, a colon cancer, an endometrial cancer, a glioma, a head and neck cancer, a head and neck squamous cell cancer, a leukemia, a liver cancer, a lung cancer, a non-small cell lung cancer, a small cell lung cancer, a lymphoma, a melanoma, an oropharyngeal cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a metastatic castration-resistant prostate carcinoma, a renal cancer, a sarcoma, a skin cancer, a squamous cell cancer, a stomach cancer, a testis cancer, a thyroid cancer, a urogenital cancer, or a urothelial cancer.

### Claim 94 (depends on 40)

A method of inhibiting or reducing the growth, proliferation, or metastasis of cells expressing mammalian CD71 comprising administering a therapeutically effective amount of the conjugated activatable antibody of claim 40 to a subject in need thereof.

### Claim 95 (depends on 6)

A method of inhibiting, blocking, or preventing the binding of a natural ligand to mammalian CD71, comprising administering a therapeutically effective amount of the activatable antibody of claim 6 to a subject in need thereof.

### Claim 96 (depends on 95)

The method of claim 95, wherein the natural ligand is transferrin.

### Claim 97 (depends on 94)

The method of claim 94, wherein the expression and/or activity of the mammalian CD71 is aberrant.

### Claim 98 (depends on 89)

The method of claim 89, wherein the method comprises administering an additional agent.

### Claim 99 (depends on 98)

The method of claim 98, wherein the additional agent is a therapeutic agent.

### Claim 100 (depends on 40)

A pharmaceutical composition comprising the conjugated activatable antibody of claim 40; and a carrier.

### Claim 101 (depends on 100)

The pharmaceutical composition of claim 100 comprising an additional agent.

### Claim 102 (depends on 90)

The method of claim 90, wherein the cancer is an adenocarcinoma, a bile duct (biliary) cancer, a bladder cancer, a bone cancer, a breast cancer, a triple-negative breast cancer, a Her2-negative breast cancer, a carcinoid cancer, a cervical cancer, a cholangiocarcinoma, a colorectal cancer, a colon cancer, an endometrial cancer, a glioma, a head and neck cancer, a head and neck squamous cell cancer, a leukemia, a liver cancer, a lung cancer, a non-small cell lung cancer, a small cell lung cancer, a lymphoma, a melanoma, an oropharyngeal cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a metastatic castration-resistant prostate carcinoma, a renal cancer, a sarcoma, a skin cancer, a squamous cell cancer, a stomach cancer, a testis cancer, a thyroid cancer, a urogenital cancer, or a urothelial cancer.

### Claim 103 (depends on 6)

The activatable antibody of claim 6, wherein the MM is linked to the CM.

### Claim 104 (depends on 6)

The activatable antibody of claim 6, wherein the MM is linked directly to the CM.

### Claim 105 (depends on 6)

The activatable antibody of claim 6, wherein the MM is linked to the CM via a linking peptide.
